Kolker, S, Garcia-Cazorla, A, Valayannopoulos, V, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: The initial presentation. J Inherit Metab Dis. 2015;38(6):1041–57.Google ScholarPubMed

Kolker, S, Valayannopoulos, V, Burlina, AB, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: The evolving clinical phenotype. J Inherit Metab Dis. 2015;38(6):1059–74.Google Scholar

Kolker, S, Sauer, SW, Hoffmann, GF, et al. Pathogenesis of CNS involvement in disorders of amino and organic acid metabolism. J Inherit Metab Dis. 2008;31(2):194–204.CrossRefGoogle ScholarPubMed

Baumgartner, MR, Horster, F, Dionisi-Vici, C, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014;9:130.CrossRefGoogle ScholarPubMed

Boy, N, Muhlhausen, C, Maier, EM, et al. Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: Second revision. J Inherit Metab Dis. 2017;40(1):75–101.CrossRefGoogle ScholarPubMed

Haberle, J, Boddaert, N, Burlina, A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012;7:32.Google Scholar

van Spronsen, FJ, van Wegberg, AM, Ahring, K, et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol. 2017;5(9):743–56.Google Scholar

Niemi, AK, Kim, IK, Krueger, CE, et al. Treatment of methylmalonic acidemia by liver or combined liver–kidney transplantation. J Pediatr. 2015;166(6):1455–61 e1.Google Scholar

Lindner, M, Gramer, G, Haege, G, et al. Efficacy and outcome of expanded newborn screening for metabolic diseases: Report of 10 years from south-west Germany. Orphanet J Rare Dis. 2011;6:44.Google Scholar

Blau, N, van Spronsen, FJ, Levy, HL. Phenylketonuria. Lancet. 2010;376(9750):1417–27.Google Scholar

Pietz, J, Kreis, R, Rupp, A, et al. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest. 1999;103(8):1169–78.CrossRefGoogle ScholarPubMed

Burgard, P, Schmidt, E, Rupp, A, Schneider, W, Bremer, HJ. Intellectual development of the patients of the German collaborative study of children treated for phenylketonuria. Eur J Pediatr. 1996;155 Suppl 1:S33-8.Google Scholar

van Wegberg, AMJ, MacDonald, A, Ahring, K, et al. The complete European guidelines on phenylketonuria: Diagnosis and treatment. Orphanet J Rare Dis. 2017;12:162.CrossRefGoogle ScholarPubMed

Koch, R, Hanley, W, Levy, H, et al. The Maternal Phenylketonuria International Study: 1984–2002. Pediatrics. 2003; 112 (6 Pt 2): 1523–9.Google Scholar

Muntau, AC, Roschinger, W, Habich, M, et al. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N Engl J Med. 2002;347(26):2122–32.CrossRefGoogle ScholarPubMed

Kolker, S, Burgard, P, Sauer, SW, Okun, JG. Current concepts in organic acidurias: Understanding intra- and extracerebral disease manifestation. J Inherit Metab Dis. 2013;36(4):635–44.Google Scholar

Morath, MA, Okun, JG, Muller, IB, et al. Neurodegeneration and chronic renal failure in methylmalonic aciduria: A pathophysiological approach. J Inherit Metab Dis. 2008;31(1):35–43.CrossRefGoogle ScholarPubMed

Schwab, MA, Sauer, SW, Okun, JG, et al. Secondary mitochondrial dysfunction in propionic aciduria: A pathogenic role for endogenous mitochondrial toxins. Biochem J. 2006;398(1):107–12.CrossRefGoogle ScholarPubMed

Luciani, A, Schumann, A, Berquez, M, et al. Impaired mitophagy links mitochondrial disease to epithelial stress in methylmalonyl-CoA mutase deficiency. Nat Commun. 2020;11(1):970.Google Scholar

Chandler, RJ, Zerfas, PM, Shanske, S, et al. Mitochondrial dysfunction in MUT methylmalonic acidemia. FASEB J. 2009;23(4):1252–61.CrossRefGoogle ScholarPubMed

de Keyzer, Y, Valayannopoulos, V, Benoist, JF, et al. Multiple OXPHOS deficiency in the liver, kidney, heart, and skeletal muscle of patients with methylmalonic aciduria and propionic aciduria. Pediatr Res. 2009;66(1):91–5.CrossRefGoogle ScholarPubMed

Horster, F, Baumgartner, MR, Viardot, C, et al. Long-term outcome in methylmalonic acidurias is influenced by the underlying defect (mut⁰, mut^–, cblA, cblB). Pediatr Res. 2007;62(2):225–30.Google Scholar

Baker, EH, Sloan, JL, Hauser, NS, et al. MRI characteristics of globus pallidus infarcts in isolated methylmalonic acidemia. AJNR Am J Neuroradiol. 2015;36(1):194–201.Google Scholar

Valayannopoulos, V, Baruteau, J, Delgado, MB, et al. Carglumic acid enhances rapid ammonia detoxification in classical organic acidurias with a favourable risk–benefit profile: A retrospective observational study. Orphanet J Rare Dis. 2016;11:32.Google Scholar

Sauer, SW, Okun, JG, Fricker, G, et al. Intracerebral accumulation of glutaric and 3-hydroxyglutaric acids secondary to limited flux across the blood–brain barrier constitute a biochemical risk factor for neurodegeneration in glutaryl-CoA dehydrogenase deficiency. J Neurochem. 2006;97(3):899–910.Google Scholar

Sauer, SW, Okun, JG, Schwab, MA, et al. Bioenergetics in glutaryl-coenzyme A dehydrogenase deficiency: A role for glutaryl-coenzyme A. J Biol Chem. 2005;280(23):21830–6.Google Scholar

Strauss, KA, Donnelly, P, Wintermark, M. Cerebral haemodynamics in patients with glutaryl-coenzyme A dehydrogenase deficiency. Brain. 2010;133(Pt 1):76–92.CrossRefGoogle ScholarPubMed

Tan, M, Peng, C, Anderson, KA, et al. Lysine glutarylation is a protein posttranslational modification regulated by SIRT5. Cell Metab. 2014;19(4):605–17.Google Scholar

Harting, I, Neumaier-Probst, E, Seitz, A, et al. Dynamic changes of striatal and extrastriatal abnormalities in glutaric aciduria type I. Brain. 2009;132(Pt 7):1764–82.CrossRefGoogle ScholarPubMed

Funk, CB, Prasad, AN, Frosk, P et al. Neuropathological, biochemical and molecular findings in a glutaric acidemia type 1 cohort. Brain. 2005;128(Pt 4):711–22.CrossRefGoogle Scholar

Gitiaux, C, Roze, E, Kinugawa, K, et al. Spectrum of movement disorders associated with glutaric aciduria type 1: A study of 16 patients. Mov Disord. 2008;23(16):2392–7.Google Scholar

Bjugstad, KB, Goodman, SI, Freed, CR. Age at symptom onset predicts severity of motor impairment and clinical outcome of glutaric acidemia type 1. J Pediatr. 2000;137(5):681–6.Google Scholar

Boy, N, Mengler, K, Thimm, E, et al. Newborn screening: A disease-changing intervention for glutaric aciduria type 1. Ann Neurol. 2018;83(5):970–9.CrossRefGoogle ScholarPubMed

Sauer, SW, Opp, S, Hoffmann, GF, et al. Therapeutic modulation of cerebral L-lysine metabolism in a mouse model for glutaric aciduria type I. Brain. 2011;134(Pt 1):157–70.Google Scholar

Topcu, M, Jobard, F, Halliez, S, et al. L-2-Hydroxyglutaric aciduria: Identification of a mutant gene C14orf160, localized on chromosome 14q22.1. Hum Mol Genet. 2004;13(22):2803–11.Google Scholar

Van Schaftingen, E, Rzem, R, Marbaix, A, et al. Metabolite proofreading, a neglected aspect of intermediary metabolism. J Inherit Metab Dis. 2013;36(3):427–34.Google Scholar

Steenweg, ME, Jakobs, C, Errami, A, et al. An overview of L-2-hydroxyglutarate dehydrogenase gene (L2HGDH) variants: A genotype–phenotype study. Hum Mutat. 2010;31(4):380–90.CrossRefGoogle ScholarPubMed

Moroni, I, Bugiani, M, D’Incerti, L, et al. L-2-hydroxyglutaric aciduria and brain malignant tumors: A predisposing condition? Neurology. 2004;62(10):1882–4.Google Scholar

Patay, Z, Mills, JC, Lobel, U, et al. Cerebral neoplasms in L-2 hydroxyglutaric aciduria: 3 new cases and meta-analysis of literature data. AJNR Am J Neuroradiol. 2012;33(5):940–3.Google Scholar

Burgard, P, Kolker, S, Haege, G, Lindner, M, Hoffmann, GF. Neonatal mortality and outcome at the end of the first year of life in early onset urea cycle disorders: Review and meta-analysis of observational studies published over more than 35 years. J Inherit Metab Dis. 2016;39(2):219–29.CrossRefGoogle Scholar

Martinelli, D, Diodato, D, Ponzi, E, et al. The hyperornithinemia–hyperammonemia–homocitrullinuria syndrome. Orphanet J Rare Dis. 2015;10:29.Google Scholar

An, D, Schneller, JL, Frassetto, A, et al. Systemic messenger RNA therapy as a treatment for methylmalonic acidemia. Cell Rep. 2017;21(12):3548–58.CrossRefGoogle ScholarPubMed

De Vivo, DC, Trifiletti, RR, Jacobson, RI, et al. Defective glucose transport across the blood–brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med. 1991;325(10):703–9.Google Scholar

Wang, D, Pascual, JM, Yang, H, et al. Glut-1 deficiency syndrome: Clinical, genetic, and therapeutic aspects. Ann Neurol. 2005;57(1):111–8.CrossRefGoogle ScholarPubMed

Leen, WG, Klepper, J, Verbeek, MM, et al. Glucose transporter-1 deficiency syndrome: The expanding clinical and genetic spectrum of a treatable disorder. Brain. 2010;133(Pt 3):655–70.Google Scholar

Pearson, TS, Akman, C, Hinton, VJ, Engelstad, K, De Vivo, DC. Phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS). Curr Neurol Neurosci Rep. 2013;13(4):342.CrossRefGoogle ScholarPubMed

Alter, AS, Engelstad, K, Hinton, VJ, et al. Long-term clinical course of Glut1 deficiency syndrome. J Child Neurol. 2015;30(2):160–9.CrossRefGoogle ScholarPubMed

Hully, M, Vuillaumier-Barrot, S, Le Bizec, C, et al. From splitting GLUT1 deficiency syndromes to overlapping phenotypes. Eur J Med Genet. 2015;58(9):443–54.Google Scholar

Akman, CI, Yu, J, Alter, A, Engelstad, K, De Vivo, DC. Diagnosing glucose transporter 1 deficiency at initial presentation facilitates early treatment. J Pediatr. 2016;171:220–6.CrossRefGoogle ScholarPubMed

Pearson, TS, Pons, R, Engelstad, K, et al. Paroxysmal eye-head movements in Glut1 deficiency syndrome. Neurology. 2017;88(17):1666–73.Google Scholar

Hao, J, Kelly, DI, Su, J, Pascual, JM. Clinical aspects of glucose transporter type 1 deficiency: Information from a global registry. JAMA Neurol. 2017;74(6):727–32.Google Scholar

Coman, DJ, Sinclair, KG, Burke, CJ, et al. Seizures, ataxia, developmental delay and the general paediatrician: Glucose transporter 1 deficiency syndrome. J Paediatr Child Health. 2006;42(5):263–7.CrossRefGoogle ScholarPubMed

Larsen, J, Johannesen, KM, Ek, J, et al. The role of SLC2A1 mutations in myoclonic astatic epilepsy and absence epilepsy, and the estimated frequency of GLUT1 deficiency syndrome. Epilepsia. 2015;56(12):e203-8.Google Scholar

Ramm-Pettersen, A, Nakken, KO, Haavardsholm, KC, Selmer, KK. GLUT1-deficiency syndrome: Report of a four-generation Norwegian family with a mild phenotype. Epilepsy Behav. 2017;70(Pt A):1–4.Google Scholar

Symonds, JD, Zuberi, SM, Stewart, K, et al. Incidence and phenotypes of childhood-onset genetic epilepsies: A prospective population-based national cohort. Brain. 2019;142:2303–18.CrossRefGoogle ScholarPubMed

Brockmann, K. The expanding phenotype of GLUT1-deficiency syndrome. Brain Dev. 2009;31(7):545–52.CrossRefGoogle ScholarPubMed

Suls, A, Dedeken, P, Goffin, K, et al. Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain. 2008;131(Pt 7):1831–44.CrossRefGoogle ScholarPubMed

Arsov, T, Mullen, SA, Rogers, S, et al. Glucose transporter 1 deficiency in the idiopathic generalized epilepsies. Ann Neurol. 2012;72(5):807–15.CrossRefGoogle ScholarPubMed

Ivanova, N, Peycheva, V, Kamenarova, K, et al. Three novel SLC2A1 mutations in Bulgarian patients with different forms of genetic generalized epilepsy reflecting the clinical and genetic diversity of GLUT1-deficiency syndrome. Seizure. 2018;54:41–4.Google Scholar

Liu, Y, Bao, X, Wang, D, et al. Allelic variations of Glut-1 deficiency syndrome: The Chinese experience. Pediatr Neurol. 2012;47(1):30–4.Google Scholar

Rotstein, M, Engelstad, K, Yang, H, et al. Glut1 deficiency: Inheritance pattern determined by haploinsufficiency. Ann Neurol. 2010;68(6):955–8.Google Scholar

Barros, LF, Bittner, CX, Loaiza, A, Porras, OH. A quantitative overview of glucose dynamics in the gliovascular unit. Glia. 2007;55(12):1222–37.Google Scholar

Chugani, HT, Phelps, ME, Mazziotta, JC. Positron emission tomography study of human brain functional development. Ann Neurol. 1987;22(4):487–97.Google Scholar

Tang, M, Gao, G, Rueda, CB, et al. Brain microvasculature defects and Glut1 deficiency syndrome averted by early repletion of the glucose transporter-1 protein. Nat Commun. 2017;8:14152.CrossRefGoogle ScholarPubMed

Pascual, JM, Van Heertum, RL, Wang, D, Engelstad, K, De Vivo, DC. Imaging the metabolic footprint of Glut1 deficiency on the brain. Ann Neurol. 2002;52(4):458–64.Google Scholar

Akman, CI, Provenzano, F, Wang, D, et al. Topography of brain glucose hypometabolism and epileptic network in glucose transporter 1 deficiency. Epilepsy Res. 2015;110:206–15.CrossRefGoogle ScholarPubMed

Pons, R, Collins, A, Rotstein, M, Engelstad, K, De Vivo, DC. The spectrum of movement disorders in Glut-1 deficiency. Mov Disord. 2010;25(3):275–81.CrossRefGoogle ScholarPubMed

De Giorgis, V, Teutonico, F, Cereda, C, et al. Sporadic and familial Glut1 DS Italian patients: A wide clinical variability. Seizure. 2015;24:28–32.CrossRefGoogle Scholar

Schneider, SA, Paisan-Ruiz, C, Garcia-Gorostiaga, I, et al. GLUT1 gene mutations cause sporadic paroxysmal exercise-induced dyskinesias. Mov Disord. 2009;24(11):1684–8.Google Scholar

Koy, A, Assmann, B, Klepper, J, Mayatepek, E. Glucose transporter type 1 deficiency syndrome with carbohydrate-responsive symptoms but without epilepsy. Dev Med Child Neurol. 2011;53(12):1154–6.Google Scholar

Weber, YG, Kamm, C, Suls, A, et al. Paroxysmal choreoathetosis/spasticity (DYT9) is caused by a GLUT1 defect. Neurology. 2011;77(10):959–64.Google Scholar

Leen, WG, Taher, M, Verbeek, MM, et al. GLUT1 deficiency syndrome into adulthood: A follow-up study. J Neurol. 2014;261(3):589–99.Google Scholar

Ito, Y, Takahashi, S, Kagitani-Shimono, K, et al. Nationwide survey of glucose transporter-1 deficiency syndrome (GLUT-1DS) in Japan. Brain Dev. 2015;37(8):780–9.Google Scholar

Leary, LD, Wang, D, Nordli, DR Jr., Engelstad, K, De Vivo, DC. Seizure characterization and electroencephalographic features in Glut-1 deficiency syndrome. Epilepsia. 2003;44(5):701–7.Google Scholar

Pong, AW, Geary, BR, Engelstad, KM, et al. Glucose transporter type I deficiency syndrome: Epilepsy phenotypes and outcomes. Epilepsia. 2012;53(9):1503–10.CrossRefGoogle ScholarPubMed

Yang, H, Wang, D, Engelstad, K, et al. Glut1 deficiency syndrome and erythrocyte glucose uptake assay. Ann Neurol. 2011;70(6):996–1005.Google Scholar

Willemsen, MA, Vissers, LE, Verbeek, MM, et al. Upstream SLC2A1 translation initiation causes GLUT1 deficiency syndrome. Eur J Hum Genet. 2017;25(6):771–4.Google Scholar

Levy, B, Wang, D, Ullner, PM, et al. Uncovering microdeletions in patients with severe Glut-1 deficiency syndrome using SNP oligonucleotide microarray analysis. Mol Genet Metab. 2010;100(2):129–35.CrossRefGoogle ScholarPubMed

Friedman, JR, Thiele, EA, Wang, D, et al. Atypical GLUT1 deficiency with prominent movement disorder responsive to ketogenic diet. Mov Disord. 2006;21(2):241–5.Google Scholar

Weber, YG, Storch, A, Wuttke, TV, et al. GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. J Clin Invest. 2008;118(6):2157–68.Google Scholar

Zorzi, G, Castellotti, B, Zibordi, F, Gellera, C, Nardocci, N. Paroxysmal movement disorders in GLUT1 deficiency syndrome. Neurology. 2008;71(2):146–8.Google Scholar

Perez-Duenas, B, Prior, C, Ma, Q, et al. Childhood chorea with cerebral hypotrophy: A treatable GLUT1 energy failure syndrome. Arch Neurol. 2009;66(11):1410–4.Google Scholar

Blumenschine, M, Montes, J, Rao, AK, Engelstad, K, De Vivo, DC. Analysis of gait disturbance in Glut 1 deficiency syndrome. J Child Neurol. 2016;31(13):1483–8.Google Scholar

Anand, G, Padeniya, A, Hanrahan, D, et al. Milder phenotypes of glucose transporter type 1 deficiency syndrome. Dev Med Child Neurol. 2011;53(7):664–8.Google Scholar

Roubergue, A, Apartis, E, Mesnage, V, et al. Dystonic tremor caused by mutation of the glucose transporter gene GLUT1. J Inherit Metab Dis. 2011;34(2):483–8.Google Scholar

Gumus, H, Bayram, AK, Kardas, F, et al. The effects of ketogenic diet on seizures, cognitive functions, and other neurological disorders in classical phenotype of glucose transporter 1 deficiency syndrome. Neuropediatrics. 2015;46(5):313–20.Google Scholar

Urbizu, A, Cuenca-Leon, E, Raspall-Chaure, M, et al. Paroxysmal exercise-induced dyskinesia, writer’s cramp, migraine with aura and absence epilepsy in twin brothers with a novel SLC2A1 missense mutation. J Neurol Sci. 2010;295(1–2):110–3.Google Scholar

Pellegrin, S, Cantalupo, G, Opri, R, Dalla Bernardina, B, Darra, F. EEG findings during “paroxysmal hemiplegia” in a patient with GLUT1-deficiency. Eur J Paediatr Neurol. 2017;21(3):580–2.Google Scholar

Mochel, F, Hainque, E, Gras, D, et al. Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency. J Neurol Neurosurg Psychiatry. 2016;87(5):550–3.Google Scholar

Almuqbil, M, Rivkin, MJ, Takeoka, M, Yang, E, Rodan, LH. Transient regional cerebral hypoperfusion during a paroxysmal hemiplegic event in GLUT1 deficiency syndrome. Eur J Paediatr Neurol. 2018;22(3):544–7.Google Scholar

Rotstein, M, Doran, J, Yang, H, et al. Glut1 deficiency and alternating hemiplegia of childhood. Neurology. 2009;73(23):2042–4.Google Scholar

Weller, CM, Leen, WG, Neville, BG, et al. A novel SLC2A1 mutation linking hemiplegic migraine with alternating hemiplegia of childhood. Cephalalgia. 2015;35(1):10–5.Google Scholar

Mohammad, SS, Coman, D, Calvert, S. Glucose transporter 1 deficiency syndrome and hemiplegic migraines as a dominant presenting clinical feature. J Paediatr Child Health. 2014;50(12):1025–6.Google Scholar

Appavu, B, Mangum, T, Obeid, M. Glucose transporter 1 deficiency: A treatable cause of opsoclonus and epileptic myoclonus. Pediatr Neurol. 2015;53(4):364–6.Google Scholar

Ohshiro-Sasaki, A, Shimbo, H, Takano, K, Wada, T, Osaka, H. A three-year-old boy with glucose transporter type 1 deficiency syndrome presenting with episodic ataxia. Pediatr Neurol. 2014;50(1):99–100.Google Scholar

Posar, A, Santucci, M. Unusual phenotype of glucose transport protein type 1 deficiency syndrome: A case report and literature review. J Pediatr Neurosci. 2014;9(1):36–8.Google Scholar

Klepper, J, Scheffer, H, Leiendecker, B, et al. Seizure control and acceptance of the ketogenic diet in GLUT1 deficiency syndrome: A 2- to 5-year follow-up of 15 children enrolled prospectively. Neuropediatrics. 2005;36(5):302–8.Google Scholar

Oguni, H, Ito, Y, Otani, Y, Nagata, S. Questionnaire survey on the current status of ketogenic diet therapy in patients with glucose transporter 1 deficiency syndrome (GLUT1DS) in Japan. Eur J Paediatr Neurol. 2018;22(3):482–7.Google Scholar

De Giorgis, V, Masnada, S, Varesio, C, et al. Overall cognitive profiles in patients with GLUT1 deficiency syndrome. Brain Behav. 2019;9(3):e01224.Google Scholar

Bekker, YAC, Lambrechts, DA, Verhoeven, JS, et al. Failure of ketogenic diet therapy in GLUT1 deficiency syndrome. Eur J Paediatr Neurol. 2019;doi:10.1016/j.ejpn.2019.02.012.Google Scholar

Tchapyjnikov, D, Mikati, MA. Acetazolamide-responsive episodic ataxia without baseline deficits or seizures secondary to GLUT1 deficiency: A case report and review of the literature. Neurologist. 2018;23(1):17–8.Google Scholar

Pascual, JM, Liu, P, Mao, D, et al. Triheptanoin for glucose transporter type 1 deficiency (G1D): Modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement. JAMA Neurol. 2014;71(10):1255–65.Google Scholar

Hainque, E, Gras, D, Meneret, A, et al. Long-term follow-up in an open-label trial of triheptanoin in GLUT1 deficiency syndrome: A sustained dramatic effect. J Neurol Neurosurg Psychiatry. 2019;doi:10.1136/jnnp-2018-320283.Google Scholar

Nakamura, S, Muramatsu, SI, Takino, N, et al. Gene therapy for Glut1-deficient mouse using an adeno-associated virus vector with the human intrinsic GLUT1 promoter. J Gene Med. 2018;20(4):e3013.Google Scholar

Patterson, MC, Clayton, P, Gissen, P, et al. Recommendations for the detection and diagnosis of Niemann–Pick disease type C: An update. Neurol Clin Pract. 2017;7(6):499–511.Google Scholar

Hers, HG. Inborn lysosomal diseases. Gastroenterology. 1965;48:625–33.Google Scholar

Carstea, ED, Morris, JA, Coleman, KG, et al. Niemann–Pick C1 disease gene: Homology to mediators of cholesterol homeostasis. Science. 1997;277(5323):228–31.Google Scholar

Naureckiene, S, Sleat, DE, Lackland, H, et al. Identification of HE1 as the second gene of Niemann–Pick C disease. Science. 2000;290(5500):2298–301.Google Scholar

Lloyd-Evans, E, Platt, FM. Lipids on trial: The search for the offending metabolite in Niemann–Pick type C disease. Traffic. 2010;11(4):419–28.Google Scholar

Vanier, MT. Complex lipid trafficking in Niemann–Pick disease type C. J Inherit Metab Dis. 2015;38(1):187–99.Google Scholar

Higashi, Y, Murayama, S, Pentchev, PG, Suzuki, K. Cerebellar degeneration in the Niemann–Pick type C mouse. Acta Neuropathol. 1993;85(2):175–84.Google Scholar

Vanier, MT. Prenatal diagnosis of Niemann–Pick diseases types A, B and C. Prenat Diagn. 2002;22(7):630–2.CrossRefGoogle ScholarPubMed

Sarna, JR, Larouche, M, Marzban, H, et al. Patterned Purkinje cell degeneration in mouse models of Niemann–Pick type C disease. J Comp Neurol. 2003;456(3):279–91.Google Scholar

Luan, Z, Saito, Y, Miyata, H, et al. Brainstem neuropathology in a mouse model of Niemann–Pick disease type C. J Neurol Sci. 2008;268(1–2):108–16.Google Scholar

Paul, CA, Boegle, AK, Maue, RA. Before the loss: Neuronal dysfunction in Niemann–Pick type C disease. Biochim Biophys Acta. 2004;1685(1–3):63–76.Google Scholar

Zafeiriou, DI, Triantafyllou, P, Gombakis, NP, et al. Niemann–Pick type C disease associated with peripheral neuropathy. Pediatr Neurol. 2003;29(3):242–4.CrossRefGoogle ScholarPubMed

Chien, YH, Lee, NC, Tsai, LK, et al. Treatment of Niemann–Pick disease type C in two children with miglustat: Initial responses and maintenance of effects over 1 year. J Inherit Metab Dis. 2007;30(5):826.Google Scholar

Bagel, JH, Sikora, TU, Prociuk, M, et al. Electrodiagnostic testing and histopathologic changes confirm peripheral nervous system myelin abnormalities in the feline model of Niemann–Pick disease type C. J Neuropathol Exp Neurol. 2013;72(3):256–62.CrossRefGoogle ScholarPubMed

Vanier, MT. Niemann–Pick disease type C. Orphanet J Rare Dis. 2010;5:16.Google Scholar

Ebrahimi-Fakhari, D, Hildebrandt, C, Davis, PE, et al. The spectrum of movement disorders in childhood-onset lysosomal storage diseases. Mov Disord Clin Pract. 2018;5(2):149–55.Google Scholar

Salsano, E, Umeh, C, Rufa, A, Pareyson, D, Zee, DS. Vertical supranuclear gaze palsy in Niemann–Pick type C disease. Neurol Sci. 2012;33(6):1225–32.Google Scholar

Solomon, D, Winkelman, AC, Zee, DS, Gray, L, Buttner-Ennever, J. Niemann–Pick type C disease in two affected sisters: Ocular motor recordings and brain-stem neuropathology. Ann N Y Acad Sci. 2005;1039:436–45.Google Scholar

Crespi, J, Brathen, G, Quist-Paulsen, P, Pagonabarraga, J, Roig-Arnall, C. Facial dystonia with facial grimacing and vertical gaze palsy with “round the houses” sign in a 29-year-old woman. Neuroophthalmology. 2016;40(1):31–4.Google Scholar

Patterson, MC, Vecchio, D, Prady, H, Abel, L, Wraith, JE. Miglustat for treatment of Niemann–Pick C disease: A randomised controlled study. Lancet Neurol. 2007;6(9):765–72.Google Scholar

Abel, LA, Walterfang, M, Fietz, M, Bowman, EA, Velakoulis, D. Saccades in adult Niemann–Pick disease type C reflect frontal, brainstem, and biochemical deficits. Neurology. 2009;72(12):1083–6.Google Scholar

Abel, LA, Bowman, EA, Velakoulis, D, et al. Saccadic eye movement characteristics in adult Niemann–Pick Type C disease: Relationships with disease severity and brain structural measures. PLoS One. 2012;7(11):e50947.Google Scholar

Stein, VM, Crooks, A, Ding, W, et al. Miglustat improves Purkinje cell survival and alters microglial phenotype in feline Niemann–Pick disease type C. J Neuropathol Exp Neurol. 2012;71(5):434–48.Google Scholar

Zesiewicz, TA, Wilmot, G, Kuo, SH, et al. Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(10):464–71.Google Scholar

Geberhiwot, T, Moro, A, Dardis, A, et al. Consensus clinical management guidelines for Niemann–Pick disease type C. Orphanet J Rare Dis. 2018;13:50.Google Scholar

Ferber-Viart, C, Dubreuil, C, Vidal, PP. Effects of acetyl-DL-leucine in vestibular patients: A clinical study following neurotomy and labyrinthectomy. Audiol Neurootol. 2009;14(1):17–25.Google Scholar

Highstein, SM, Holstein, GR. The anatomy of the vestibular nuclei. Prog Brain Res. 2006;151:157–203.Google Scholar

Strupp, M, Teufel, J, Habs, M, Feuerecker, R, Muth, C, van de Warrenburg, BP, et al. Effects of acetyl-DL-leucine in patients with cerebellar ataxia: A case series. J Neurol. 2013;260(10):2556–61.Google Scholar

Pelz, JO, Fricke, C, Saur, D, Classen, J. Failure to confirm benefit of acetyl-DL-leucine in degenerative cerebellar ataxia: A case series. J Neurol. 2015;262(5):1373–5.Google Scholar

Bremova, T, Malinova, V, Amraoui, Y, et al. Acetyl-DL-leucine in Niemann–Pick type C: A case series. Neurology. 2015;85(16):1368–75.Google Scholar

Abe, K, Sakai, N. Patient with Niemann–Pick disease type C: Over 20 years’ follow-up. BMJ Case Rep. 2017;2017.Google Scholar

Anheim, M, Lagha-Boukbiza, O, Fleury-Lesaunier, MC, et al. Heterogeneity and frequency of movement disorders in juvenile and adult-onset Niemann–Pick C disease. J Neurol. 2014;261(1):174–9.Google Scholar

Vankova, J, Stepanova, I, Jech, R, et al. Sleep disturbances and hypocretin deficiency in Niemann–Pick disease type C. Sleep. 2003;26(4):427–30.Google Scholar

Josephs, KA, Van Gerpen, MW, Van Gerpen, JA. Adult onset Niemann–Pick disease type C presenting with psychosis. J Neurol Neurosurg Psychiatry. 2003;74(4):528–9.CrossRefGoogle ScholarPubMed

Koens, LH, Kuiper, A, Coenen, MA, et al. Ataxia, dystonia and myoclonus in adult patients with Niemann–Pick type C. Orphanet J Rare Dis. 2016;11:121.Google Scholar

Floyd, AG, Yu, QP, Piboolnurak, P, et al. Kinematic analysis of motor dysfunction in Niemann–Pick type C. Clin Neurophysiol. 2007;118(5):1010–8.Google Scholar

Hsu, AW, Piboolnurak, PA, Floyd, AG, et al. Spiral analysis in Niemann–Pick disease type C. Mov Disord. 2009;24(13):1984–90.Google Scholar

Pineda, M, Wraith, JE, Mengel, E, et al. Miglustat in patients with Niemann–Pick disease type C (NP–C): A multicenter observational retrospective cohort study. Mol Genet Metab. 2009;98(3):243–9.Google Scholar

Patterson, MC, Vecchio, D, Jacklin, E, et al. Long-term miglustat therapy in children with Niemann–Pick disease type C. J Child Neurol. 2010;25(3):300–5.Google Scholar

Scheel, M, Abegg, M, Lanyon, LJ, Mattman, A, Barton, JJ. Eye movement and diffusion tensor imaging analysis of treatment effects in a Niemann–Pick type C patient. Mol Genet Metab. 2010;99(3):291–5.Google Scholar

Wraith, JE, Vecchio, D, Jacklin, E, et al. Miglustat in adult and juvenile patients with Niemann–Pick disease type C: Long-term data from a clinical trial. Mol Genet Metab. 2010;99(4):351–7.CrossRefGoogle ScholarPubMed

Heron, B, Valayannopoulos, V, Baruteau, J, et al. Miglustat therapy in the French cohort of paediatric patients with Niemann–Pick disease type C. Orphanet J Rare Dis. 2012;7:36.Google Scholar

Abel, LA, Walterfang, M, Stainer, MJ, Bowman, EA, Velakoulis, D. Longitudinal assessment of reflexive and volitional saccades in Niemann–Pick type C disease during treatment with miglustat. Orphanet J Rare Dis. 2015;10:160.CrossRefGoogle ScholarPubMed

Patterson, MC, Mengel, E, Vanier, MT, et al. Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann–Pick disease type C: An observational cohort study. Orphanet J Rare Dis. 2015;10:65.Google Scholar

Sedel, F, Chabrol, B, Audoin, B, et al. Normalisation of brain spectroscopy findings in Niemann–Pick disease type C patients treated with miglustat. J Neurol. 2016;263(5):927–36.Google Scholar

Liu, B, Turley, SD, Burns, DK, et al. Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the NPC1-/- mouse. Proc Natl Acad Sci USA. 2009;106(7):2377–82.Google Scholar

Davidson, CD, Ali, NF, Micsenyi, MC, et al. Chronic cyclodextrin treatment of murine Niemann–Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS One. 2009;4(9):e6951.Google Scholar

Vite, CH, Bagel, JH, Swain, GP, et al. Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann–Pick type C1 disease. Sci Transl Med. 2015;7(276):276ra26.Google Scholar

Berry-Kravis, E, Chin, J, Hoffmann, A, et al. Long-term treatment of Niemann–Pick type C1 disease with intrathecal 2-hydroxypropyl-beta-cyclodextrin. Pediatr Neurol. 2018;80:24–34.Google Scholar

Mole, SE, Williams, RE. Neuronal ceroid-lipofuscinoses. GeneReviews®. 2001;Oct 10 (updated Aug 1, 2013).Google Scholar

Nita, DA, Mole, SE, Minassian, BA. Neuronal ceroid lipofuscinoses. Epileptic Disord. 2016;18(S2):73–88.Google Scholar

Mink, JW, Augustine, EF, Adams, HR, Marshall, FJ, Kwon, JM. Classification and natural history of the neuronal ceroid lipofuscinoses. J Child Neurol. 2013;28(9):1101–5.Google Scholar

Mole, SE, Cotman, SL. Genetics of the neuronal ceroid lipofuscinoses (Batten disease). Biochim Biophys Acta. 2015;1852(10 Pt B):2237–41.Google Scholar

Santavuori, P, Haltia, M, Rapola, J. Infantile type of so-called neuronal ceroid-lipofuscinosis. Dev Med Child Neurol. 1974;16(5):644–53.Google Scholar

Becker, K, Goebel, HH, Svennerholm, L, Wendel, U, Bremer, HJ. Clinical, morphological, and biochemical investigations on a patient with an unusual form of neuronal ceroid-lipofuscinosis. Eur J Pediatr. 1979;132(3):197–206.Google Scholar

Das, AK, Becerra, CH, Yi, W, et al. Molecular genetics of palmitoyl-protein thioesterase deficiency in the U.S. J Clin Invest. 1998;102(2):361–70.Google Scholar

Ramadan, H, Al-Din, AS, Ismail, A, et al. Adult neuronal ceroid lipofuscinosis caused by deficiency in palmitoyl protein thioesterase 1. Neurology. 2007;68(5):387–8.Google Scholar

van Diggelen, OP, Thobois, S, Tilikete, C, et al. Adult neuronal ceroid lipofuscinosis with palmitoyl-protein thioesterase deficiency: First adult-onset patients of a childhood disease. Ann Neurol. 2001;50(2):269–72.Google Scholar

Wisniewski, KE, Connell, F, Kaczmarski, W, et al. Palmitoyl-protein thioesterase deficiency in a novel granular variant of LINCL. Pediatr Neurol. 1998;18(2):119–23.CrossRefGoogle Scholar

Steinfeld, R, Heim, P, von Gregory, H, et al. Late infantile neuronal ceroid lipofuscinosis: Quantitative description of the clinical course in patients with CLN2 mutations. Am J Med Genet. 2002;112(4):347–54.Google Scholar

Ku, CA, Hull, S, Arno, G, et al. Detailed clinical phenotype and molecular genetic findings in CLN3-associated isolated retinal degeneration. JAMA Ophthalmol. 2017;135(7):749–60.Google Scholar

Khan, KN, El-Asrag, ME, Ku, CA, et al. Specific alleles of CLN7/MFSD8, a protein that localizes to photoreceptor synaptic terminals, cause a spectrum of nonsyndromic retinal dystrophy. Invest Ophthalmol Vis Sci. 2017;58(7):2906–14.Google Scholar

Mole, SE, Anderson, G, Band, HA, et al. Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis. Lancet Neurol. 2019;18(1):107–16.CrossRefGoogle ScholarPubMed

Berkovic, SF, Staropoli, JF, Carpenter, S, et al. Diagnosis and misdiagnosis of adult neuronal ceroid lipofuscinosis (Kufs disease). Neurology. 2016;87(6):579–84.Google Scholar

Mahajnah, M, Zelnik, N. Phenotypic heterogeneity in consanguineous patients with a common CLN8 mutation. Pediatr Neurol. 2012;47(4):303–5.Google Scholar

Cassim, F, Houdayer, E. Neurophysiology of myoclonus. Neurophysiol Clin. 2006; 36 (5-6): 281–91.Google Scholar

Bergman, H, Wichmann, T, DeLong, MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science. 1990;249(4975):1436–8.Google Scholar

DeLong, MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990;13(7):281–5.Google Scholar

Schulz, A, Kohlschutter, A, Mink, J, Simonati, A, Williams, R. NCL diseases: Clinical perspectives. Biochim Biophys Acta. 2013;1832(11):1801–6.Google Scholar

Vesa, J, Hellsten, E, Verkruyse, LA, et al. Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature. 1995;376(6541):584–7.Google Scholar

Lerner, TJ, Boustany, R-MN, Anderson, JW, et al. Isolation of a novel gene underlying Batten disease, CLN3. Cell. 1995;82(6):949–57.Google Scholar

Smith, KR, Dahl, HH, Canafoglia, L, et al. Cathepsin F mutations cause type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis. Hum Mol Genet. 2013;22(7):1417–23.Google Scholar

Vanhanen, SL, Puranen, J, Autti, T, et al. Neuroradiological findings (MRS, MRI, SPECT) in infantile neuronal ceroid-lipofuscinosis (infantile CLN1) at different stages of the disease. Neuropediatrics. 2004;35(1):27–35.Google Scholar

Riikonen, R, Vanhanen, SL, Tyynela, J, Santavuori, P, Turpeinen, U. CSF insulin-like growth factor-1 in infantile neuronal ceroid lipofuscinosis. Neurology. 2000;54(9):1828–32.Google Scholar

Levin, SW, Baker, EH, Zein, WM, et al. Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: A pilot study. Lancet Neurol. 2014;13(8):777–87.CrossRefGoogle ScholarPubMed

Confort-Gouny, S, Chabrol, B, Vion-Dury, J, Mancini, J, Cozzone, PJ.MRI and localized proton MRS in early infantile form of neuronal ceroid-lipofuscinosis. Pediatr Neurol. 1993;9(1):57–60.Google Scholar

Metelitsina, TI, Waggoner, DJ, Grassi, MA. Batten disease caused by a novel mutation in the PPT1 gene. Retin Cases Brief Rep. 2016;10(3):211–3.Google Scholar

Nickel, M, Schulz, A, Kohlschütter, A, et al. PP03.8 – 2898: Late language acquisition and unexplained epilepsy are indicators of easily detectable CLN2 disease. Eur J Paediatr Neuro. 2015;19:S38.Google Scholar

Nickel, M, Simonati, A, Jacoby, D, et al. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health. 2018;2(8):582–90.Google Scholar

Williams, RE, Adams, HR, Blohm, M, et al. Management strategies for CLN2 disease. Pediatr Neurol. 2017;69:102–12.Google Scholar

Saini, AG, Sankhyan, N, Singhi, P. Chorea in late-infantile neuronal ceroid lipofuscinosis: An atypical presentation. Pediatr Neurol. 2016;60:75–8.Google Scholar

Di Giacopo, R, Cianetti, L, Caputo, V, et al. Protracted late infantile ceroid lipofuscinosis due to TPP1 mutations: Clinical, molecular and biochemical characterization in three sibs. J Neurol Sci . 2015;356(1):65–71.Google Scholar

Johannsen, J, Nickel, M, Schulz, A, Denecke, J. Considering valproate as a risk factor for rapid exacerbation of complex movement disorder in progressed stages of late-infantile CLN2 disease. Neuropediatrics. 2016;47(3):194–6.Google Scholar

Sun, Y, Almomani, R, Breedveld, GJ, et al. Autosomal recessive spinocerebellar ataxia 7 (SCAR7) is caused by variants in TPP1, the gene involved in classic late-infantile neuronal ceroid lipofuscinosis 2 disease (CLN2 disease). Hum Mutat. 2013;34(5):706–13.Google Scholar

Dy, ME, Sims, KB, Friedman, J. TPP1 deficiency: Rare cause of isolated childhood-onset progressive ataxia. Neurology. 2015;85(14):1259–61.Google Scholar

Marshall, FJ, de Blieck, EA, Mink, JW, et al. A clinical rating scale for Batten disease: Reliable and relevant for clinical trials. Neurology. 2005;65(2):275–9.Google Scholar

Cialone, J, Adams, H, Augustine, EF, et al. Females experience a more severe disease course in Batten disease. J Inherit Metab Dis. 2012;35(3):549–55.Google Scholar

Ostergaard, JR. Juvenile neuronal ceroid lipofuscinosis (Batten disease): Current insights. Degener Neurol Neuromuscul Dis. 2016;6:73–83.Google Scholar

Ostergaard, JR, Rasmussen, TB, Molgaard, H. Cardiac involvement in juvenile neuronal ceroid lipofuscinosis (Batten disease). Neurology. 2011;76(14):1245–51.Google Scholar

Elkay, M, Silver, K, Penn, RD, Dalvi, A. Dystonic storm due to Batten’s disease treated with pallidotomy and deep brain stimulation. Mov Disord. 2009;24(7):1048–53.Google Scholar

Hofman, IL. Observations in institutionalized neuronal ceroid-lipofuscinosis patients with special reference to involuntary movements. J Inherit Metab Dis. 1993;16(2):249–51.Google Scholar

Aberg, L, Liewendahl, K, Nikkinen, P, et al. Decreased striatal dopamine transporter density in JNCL patients with parkinsonian symptoms. Neurology. 2000;54(5):1069–74.Google Scholar

Rinne, JO, Ruottinen, HM, Nagren, K, Aberg, LE, Santavuori, P. Positron emission tomography shows reduced striatal dopamine D1 but not D2 receptors in juvenile neuronal ceroid lipofuscinosis. Neuropediatrics. 2002;33(3):138–41.Google Scholar

Boehme, DH, Cottrell, JC, Leonberg, SC, Zeman, W. A dominant form of neuronal ceroid-lipofuscinosis. Brain. 1971;94(4):745–60.Google Scholar

Ferrer, I, Arbizu, T, Pena, J, Serra, JP. A golgi and ultrastructural study of a dominant form of Kufs’ disease. J Neurol. 1980;222(3):183–90.Google Scholar

Josephson, SA, Schmidt, RE, Millsap, P, McManus, DQ, Morris, JC. Autosomal dominant Kufs’ disease: A cause of early onset dementia. J Neurol Sci. 2001; 188 (1-2): 51–60.Google Scholar

Burneo, JG, Arnold, T, Palmer, CA, et al. Adult-onset neuronal ceroid lipofuscinosis (Kufs disease) with autosomal dominant inheritance in Alabama. Epilepsia. 2003;44(6):841–6.Google Scholar

Simonati, A, Williams, RE, Nardocci, N, et al. Phenotype and natural history of variant late infantile ceroid-lipofuscinosis 5. Dev Med Child Neurol. 2017;59(8):815–21.Google Scholar

Mancini, C, Nassani, S, Guo, Y, et al. Adult-onset autosomal recessive ataxia associated with neuronal ceroid lipofuscinosis type 5 gene (CLN5) mutations. J Neurol. 2015;262(1):173–8.Google Scholar

Sharp, JD, Wheeler, RB, Lake, BD, et al. Loci for classical and a variant late infantile neuronal ceroid lipofuscinosis map to chromosomes 11p15 and 15q21-23. Hum Mol Genet. 1997;6(4):591–5.Google Scholar

Berkovic, SF, Oliver, KL, Canafoglia, L, et al. Kufs disease due to mutation of CLN6: Clinical, pathological and molecular genetic features. Brain. 2019;142(1):59–69.Google Scholar

Arsov, T, Smith, KR, Damiano, J, et al. Kufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in CLN6. Am J Hum Genet. 2011;88(5):566–73.Google Scholar

Canafoglia, L, Gilioli, I, Invernizzi, F, et al. Electroclinical spectrum of the neuronal ceroid lipofuscinoses associated with CLN6 mutations. Neurology. 2015;85(4):316–24.Google Scholar

Siintola, E, Topcu, M, Kohlschutter, A, et al. Two novel CLN6 mutations in variant late-infantile neuronal ceroid lipofuscinosis patients of Turkish origin. Clin Genet. 2005;68(2):167–73.Google Scholar

Guerreiro, R, Bras, JT, Vieira, M, et al. CLN6 disease caused by the same mutation originating in Pakistan has varying pathology. Eur J Paediatr Neurol. 2013;17(6):657–60.Google Scholar

Andrade, DM, Paton, T, Turnbull, J, et al. Mutation of the CLN6 gene in teenage-onset progressive myoclonus epilepsy. Pediatr Neurol. 2012;47(3):205–8.Google Scholar

Ozkara, C, Gunduz, A, Coskun, T, et al. Long-term follow-up of two siblings with adult-onset neuronal ceroid lipofuscinosis, Kufs type A. Epileptic Disord. 2017;19(2):147–51.Google Scholar

Topcu, M, Tan, H, Yalnizoglu, D, et al. Evaluation of 36 patients from Turkey with neuronal ceroid lipofuscinosis: Clinical, neurophysiological, neuroradiological and histopathologic studies. Turkish J Pediatr. 2004;46(1):1–10.Google Scholar

Siintola, E, Topcu, M, Aula, N, et al. The novel neuronal ceroid lipofuscinosis gene MFSD8 encodes a putative lysosomal transporter. Am J Hum Genet. 2007;81(1):136-46.Google Scholar

Mandel, H, Cohen Katsanelson, K, Khayat, M, et al. Clinico-pathological manifestations of variant late infantile neuronal ceroid lipofuscinosis (vLINCL) caused by a novel mutation in MFSD8 gene. Eur J Med Genet. 2014;57(11-12):607–12.Google Scholar

Craiu, D, Dragostin, O, Dica, A, et al. Rett-like onset in late-infantile neuronal ceroid lipofuscinosis (CLN7) caused by compound heterozygous mutation in the MFSD8 gene and review of the literature data on clinical onset signs. Eur J Paediatr Neuro. 2015;19(1):78–86.Google Scholar

Striano, P, Specchio, N, Biancheri, R, et al. Clinical and electrophysiological features of epilepsy in Italian patients with CLN8 mutations. Epilepsy Behav. 2007;10(1):187–91.Google Scholar

Katata, Y, Uematsu, M, Sato, H, et al. Novel missense mutation in CLN8 in late infantile neuronal ceroid lipofuscinosis: The first report of a CLN8 mutation in Japan. Brain Dev-JPN. 2016;38(3):341–5.Google Scholar

Reinhardt, K, Grapp, M, Schlachter, K, et al. Novel CLN8 mutations confirm the clinical and ethnic diversity of late infantile neuronal ceroid lipofuscinosis. Clin Genet. 2010;77(1):79–85.Google Scholar

Beesley, C, Guerreiro, RJ, Bras, JT, et al. CLN8 disease caused by large genomic deletions. Mol Genet Genomic Med. 2017;5(1):85–91.Google Scholar

Gao, Z, Xie, H, Jiang, Q, et al. Identification of two novel null variants in CLN8 by targeted next-generation sequencing: First report of a Chinese patient with neuronal ceroid lipofuscinosis due to CLN8 variants. BMC Med Genet. 2018;19(1):21.Google Scholar

Allen, NM, O’hIci, B, Anderson, G, et al. Variant late-infantile neuronal ceroid lipofuscinosis due to a novel heterozygous CLN8 mutation and de novo 8p23.3 deletion. Clinical Genetics. 2012;81(6):602–4.Google Scholar

Steinfeld, R, Reinhardt, K, Schreiber, K, et al. Cathepsin D deficiency is associated with a human neurodegenerative disorder. Am J Hum Genet. 2006;78(6):988–98.Google Scholar

Doccini, S, Sartori, S, Maeser, S, et al. Early infantile neuronal ceroid lipofuscinosis (CLN10 disease) associated with a novel mutation in CTSD. J Neurol. 2016;263(5):1029–32.Google Scholar

Norman, RM, Wood, N. A congenital form of amaurotic family idiocy. J Neurol Psychiatry. 1941; 4 (3-4): 175–90.Google Scholar

Barohn, RJ, Dowd, DC, Kagan-Hallet, KS. Congenital ceroid-lipofuscinosis. Pediatr Neurol. 1992;8(1):54–9.Google Scholar

Brown, NJ, Corner, BD, Dodgson, MC. A second case in the same family of congenital familial cerebral lipoidosis resembling amaurotic family idiocy. Arch Dis Child. 1954;29(143):48–54.Google Scholar

Garborg, I, Torvik, A, Hals, J, Tangsrud, SE, Lindemann, R. Congenital neuronal ceroid lipofuscinosis. A case report. Acta Pathol Microbiol Immunol Scand A. 1987;95(3):119–25.Google Scholar

Humphreys, S, Lake, BD, Scholtz, CL. Congenital amaurotic idiocy: Pathological, histochemical, biochemical and ultrastructural study. Neuropathol Appl Neurobiol. 1985;11(6):475–84.Google Scholar

Sandbank, U. Congenital amaurotic idiocy. Pathol Eur. 1968;3(2):226–9.Google Scholar

Fritchie, K, Siintola, E, Armao, D, et al. Novel mutation and the first prenatal screening of cathepsin D deficiency (CLN10). Acta Neuropathol. 2009;117(2):201–8.Google Scholar

Varvagiannis, K, Hanquinet, S, Billieux, MH, et al. Congenital neuronal ceroid lipofuscinosis with a novel CTSD gene mutation: A rare cause of neonatal-onset neurodegenerative disorder. Neuropediatrics. 2018;49(2):150–3.Google Scholar

Siintola, E, Partanen, S, Stromme, P, et al. Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. Brain. 2006;129(Pt 6):1438–45.Google Scholar

Hersheson, J, Burke, D, Clayton, R, et al. Cathepsin D deficiency causes juvenile-onset ataxia and distinctive muscle pathology. Neurology. 2014;83(20):1873–5.Google Scholar

Canafoglia, L, Morbin, M, Scaioli, V, et al. Recurrent generalized seizures, visual loss, and palinopsia as phenotypic features of neuronal ceroid lipofuscinosis due to progranulin gene mutation. Epilepsia. 2014;55(6):e56–9.Google Scholar

Almeida, MR, Macario, MC, Ramos, L, et al. Portuguese family with the co-occurrence of frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis phenotypes due to progranulin gene mutation. Neurobiol Aging. 2016;41:200.e1–5.Google Scholar

Smith Katherine, R, Damiano, J, Franceschetti, S, et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet . 2012;90(6):1102-7.Google Scholar

Ramirez, A, Heimbach, A, Grundemann, J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet. 2006;38(10):1184–91.Google Scholar

Estrada-Cuzcano, A, Martin, S, Chamova, T, et al. Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78). Brain. 2017;140(2):287–305.Google Scholar

Bras, J, Verloes, A, Schneider, SA, Mole, SE, Guerreiro, RJ. Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis. Hum Mol Genet. 2012;21(12):2646–50.Google Scholar

Di Fabio, R, Moro, F, Pestillo, L, et al. Pseudo-dominant inheritance of a novel CTSF mutation associated with type B Kufs disease. Neurology. 2014;83(19):1769–70.Google Scholar

Di Fabio, R, Colonnese, C, Santorelli, FM, Pestillo, L, Pierelli, F. Brain imaging in Kufs disease type B: Case reports. BMC Neurol. 2015;15:102.Google Scholar

Van Bogaert, P, Azizieh, R, Desir, J, et al. Mutation of a potassium channel-related gene in progressive myoclonic epilepsy. Ann Neurol. 2007;61(6):579–86.Google Scholar

Farhan, SM, Murphy, LM, Robinson, JF, et al. Linkage analysis and exome sequencing identify a novel mutation in KCTD7 in patients with progressive myoclonus epilepsy with ataxia. Epilepsia. 2014;55(9):e106–11.Google Scholar

Staropoli, JF, Karaa, A, Lim, ET, et al. A homozygous mutation in KCTD7 links neuronal ceroid lipofuscinosis to the ubiquitin-proteasome system. Am J Hum Genet. 2012;91(1):202–8.Google Scholar

Mastrangelo, M, Sartori, S, Simonati, A, et al. Progressive myoclonus epilepsy and ceroidolipofuscinosis 14: The multifaceted phenotypic spectrum of KCTD7-related disorders. Eur J Med Genet. 2019;62(12):103591. doi:10.1016/j.Google Scholar

Metz, KA, Teng, X, Coppens, I, et al. KCTD7 deficiency defines a distinct neurodegenerative disorder with a conserved autophagy-lysosome defect. Ann Neurol. 2018;84(5):766-80.Google Scholar

Koy, A, Lin, JP, Sanger, TD, et al. Advances in management of movement disorders in children. Lancet Neurol. 2016;15(7):719–35.Google Scholar

Singer, HS, Mink, JW, Glibert, DL, Jankovic, J. Movement Disorders in Childhood, 2nd edn. Philadelphia, PA: Academic Press; 2015.Google Scholar

Åberg, L, Liewendahl, K, Nikkinen, P, et al. Decreased striatal dopamine transporter density in JNCL patients with parkinsonian symptoms. Neurology. 2000;54(5):1069-74.Google Scholar

Åberg, LE, Rinne, JO, Rajantie, I, Santavuori, P. A favorable response to anitparkinsonian treatment in juvenile neuronal ceroid lipofucinosis. Neurology. 2001;56(9):1236-9.Google Scholar

Zweije-Hofman, IL, van der Zee, HJ, van Nieuwenhuizen, O. Anti-parkinson drugs in the Batten–Spielmeyer–Vogt syndrome: A pilot trial. Clin Neurol Neurosurg. 1982;84(2):101–5.Google Scholar

Gospe, SM, Jr., Jankovic, J. Drug-induced dystonia in neuronal ceroid-lipofuscinosis. Pediatr Neurol. 1986;2(4):236–7.Google Scholar

Vercammen, L, Buyse, GM, Proost, JE, Van Hove, JL. Neuroleptic malignant syndrome in juvenile neuronal ceroid lipofuscinosis associated with low-dose risperidone therapy. J Inherit Metab Dis. 2003;26(6):611–2.Google Scholar

Barisic, N, Logan, P, Pikija, S, Skarpa, D, Blau, N. R208X mutation in CLN2 gene associated with reduced cerebrospinal fluid pterins in a girl with classic late infantile neuronal ceroid lipofuscinosis. Croat Med J. 2003;44(4):489–93.Google Scholar

Le, NM, Parikh, S. Late infantile neuronal ceroid lipofuscinosis and dopamine deficiency. J Child Neurol. 2012;27(2):234–7.Google Scholar

Cialone, J, Blackburn, J, Mink, J. Trihexyphenidyl has cognitive side effects in children with DYT1 dystonia (IN10-2.003). Neurology. 2012;78(1Supplement):P02.177.Google Scholar

Hasegawa, H, Alkufri, F, Munro, N, et al. GPi deep brain stimulation for palliation of hemidystonia and hemibody jerking in a patient with suspected adult onset neuronal ceroid lipofuscinosis. J Neurol Sci. 2016;362:228–9.Google Scholar

Schulz, A, Ajayi, T, Specchio, N, et al. Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med. 2018;378(20):1898–907.Google Scholar

Kim, J, Hu, C, Moufawad El Achkar, C, et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Med 2019;381:1644–52.Google Scholar

Schneider, SA, Bhatia, KP. Syndromes of neurodegeneration with brain iron accumulation. Semin Pediatr Neurol. 2012;19(2):57–66.Google Scholar

Hayflick, SJ, Westaway, SK, Levinson, B, et al. Genetic, clinical, and radiographic delineation of Hallervorden–Spatz syndrome. N Engl J Med. 2003;348(1):33–40.Google Scholar

Hayflick, SJ. Neurodegeneration with brain iron accumulation: From genes to pathogenesis. Semin Pediatr Neurol. 2006;13(3):182–5.Google Scholar

Egan, RA, Weleber, RG, Hogarth, P, et al. Neuro-ophthalmologic and electroretinographic findings in pantothenate kinase-associated neurodegeneration (formerly Hallervorden–Spatz syndrome). Am J Ophthalmol. 2005;140(2):267–74.Google Scholar

Yoon, WT, Lee, WY, Shin, HY, Lee, ST, Ki, CS. Novel PANK2 gene mutations in Korean patient with pantothenate kinase-associated neurodegeneration presenting unilateral dystonic tremor. Mov Disord. 2010;25(2):245–7.Google Scholar

Aggarwal, A, Schneider, SA, Houlden, H, et al. Indian-subcontinent NBIA: Unusual phenotypes, novel PANK2 mutations, and undetermined genetic forms. Mov Disord. 2010;25(10):1424–31.Google Scholar

Chung, SJ, Lee, JH, Lee, MC, Yoo, HW, Kim, GH. Focal hand dystonia in a patient with PANK2 mutation. Mov Disord. 2008;23(3):466–8.Google Scholar

Vasconcelos, OM, Harter, DH, Duffy, C, et al. Adult Hallervorden–Spatz syndrome simulating amyotrophic lateral sclerosis. Muscle Nerve. 2003;28(1):118–22.Google Scholar

Antonini, A, Goldwurm, S, Benti, R, et al. Genetic, clinical, and imaging characterization of one patient with late-onset, slowly progressive, pantothenate kinase-associated neurodegeneration. Mov Disord. 2006;21(3):417–8.Google Scholar

Seo, JH, Song, SK, Lee, PH. A novel PANK2 mutation in a patient with atypical pantothenate-kinase-associated neurodegeneration presenting with adult-onset parkinsonism. J Clin Neurol. 2009;5(4):192–4.Google Scholar

Diaz, N. Late onset atypical pantothenate-kinase-associated neurodegeneration. Case Rep Neurol Med. 2013;2013:860201.Google Scholar

Kurian, MA, Morgan, NV, MacPherson, L, et al. Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology. 2008;70(18):1623–9.Google Scholar

Morgan, NV, Westaway, SK, Morton, JE, et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet. 2006;38(7):752–4.Google Scholar

Paisan-Ruiz, C, Li, A, Schneider, SA, et al. Widespread Lewy body and tau accumulation in childhood and adult onset dystonia–parkinsonism cases with PLA2G6 mutations. Neurobiol Aging. 2012;33(4):814–23.Google Scholar

Gregory, A, Westaway, SK, Holm, IE, et al. Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology. 2008;71(18):1402–9.Google Scholar

Riku, Y, Ikeuchi, T, Yoshino, H, Mimuro, M, Mano, K, Goto, Y, et al. Extensive aggregation of alpha-synuclein and tau in juvenile-onset neuroaxonal dystrophy: An autopsied individual with a novel mutation in the PLA2G6 gene-splicing site. Acta Neuropathol Commun. 2013;1:12.Google Scholar

Hayflick, SJ, Kruer, MC, Gregory, A, et al. Beta-propeller protein-associated neurodegeneration: A new X-linked dominant disorder with brain iron accumulation. Brain. 2013;136(Pt 6):1708–17.Google Scholar

Saitsu, H, Nishimura, T, Muramatsu, K, et al. De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. Nat Genet. 2013;45(4):445–9, 9e1.Google Scholar

Verhoeven, WM, Egger, JI, Koolen, DA, et al. Beta-propeller protein-associated neurodegeneration (BPAN), a rare form of NBIA: Novel mutations and neuropsychiatric phenotype in three adult patients. Parkinsonism Relat Disord. 2013;20(3):332–6.Google Scholar

Skowronska, M, Kmiec, T, Jurkiewicz, E, et al. Evolution and novel radiological changes of neurodegeneration associated with mutations in C19orf12. Parkinsonism Relat Disord. 2017;39:71–6.Google Scholar

Dezfouli, MA, Alavi, A, Rohani, M, Rezvani, M, Nekuie, T, Klotzle, B, et al. PANK2 and C19orf12 mutations are common causes of neurodegeneration with brain iron accumulation. Mov Disord. 2013;28(2):228–32.Google Scholar

Goldman, JG, Eichenseer, SR, Berry-Kravis, E, et al. Clinical features of neurodegeneration with brain iron accumulation due to a C19orf12 gene mutation. Mov Disord. 2013;28(10):1462–3.Google Scholar

Hogarth, P, Gregory, A, Kruer, MC, et al. New NBIA subtype: Genetic, clinical, pathologic, and radiographic features of MPAN. Neurology. 2013;80(3):268–75.Google Scholar

Schulte, EC, Claussen, MC, Jochim, A, et al. Mitochondrial membrane protein associated neurodegenration: A novel variant of neurodegeneration with brain iron accumulation. Mov Disord. 2013;28(2):224–7.Google Scholar

Panteghini, C, Zorzi, G, Venco, P, et al. C19orf12 and FA2H mutations are rare in Italian patients with neurodegeneration with brain iron accumulation. Semin Pediatr Neurol. 2012;19(2):75–81.Google Scholar

Schottmann, G, Stenzel, W, Lutzkendorf, S, Schuelke, M, Knierim, E. A novel frameshift mutation of C19ORF12 causes NBIA4 with cerebellar atrophy and manifests with severe peripheral motor axonal neuropathy. Clin Genet. 2013;85(3):290–2.Google Scholar

Kruer, MC, Salih, MA, Mooney, C, et al. C19orf12 mutation leads to a pallido-pyramidal syndrome. Gene. 2014;537(2):352–6.Google Scholar

Kruer, MC, Paisan-Ruiz, C, Boddaert, N, et al. Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann Neurol. 2010;68(5):611–8.Google Scholar

Schneider, SA, Paisan-Ruiz, C, Quinn, NP, et al. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord. 2010;25(8):979–84.Google Scholar

Bruggemann, N, Hagenah, J, Reetz, K, et al. Recessively inherited parkinsonism: Effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. Arch Neurol. 2010;67(11):1357–63.Google Scholar

Behrens, MI, Bruggemann, N, Chana, P, et al. Clinical spectrum of Kufor–Rakeb syndrome in the Chilean kindred with ATP13A2 mutations. Mov Disord. 2010;25(12):1929–37.Google Scholar

Dusi, S, Valletta, L, Haack, TBet al. Exome sequence reveals mutations in CoA synthase as a cause of neurodegeneration with brain iron accumulation. Am J Hum Genet. 2014;94(1):11–22.Google Scholar

Vroegindeweij, LH, van der Beek, EH, Boon, AJ, et al. Aceruloplasminemia presents as type 1 diabetes in non-obese adults: A detailed case series. Diabet Med. 2015;32(8):993–1000.Google Scholar

Bohlega, SA, Alkuraya, FS. Woodhouse–Sakati Syndrome. 1993.Google Scholar

Horvath, R, Lewis-Smith, D, Douroudis, K, et al. SCP2 mutations and neurodegeneration with brain iron accumulation. Neurology. 2015;85(21):1909–11.Google Scholar

Ferdinandusse, S, Kostopoulos, P, Denis, S, et al. Mutations in the gene encoding peroxisomal sterol carrier protein x (SCPx) cause leukencephalopathy with dystonia and motor neuropathy. Am J Hum Genet. 2006;78(6):1046–52.Google Scholar

Jaberi, E, Rohani, M, Shahidi, GA, et al. Identification of mutation in GTPBP2 in patients of a family with neurodegeneration accompanied by iron deposition in the brain. Neurobiol Aging. 2016;38:216 e11-8.Google Scholar

Darling, A, Tello, C, Marti, MJ, et al. Clinical rating scale for pantothenate kinase-associated neurodegeneration: A pilot study. Mov Disord. 2017;32(11):1620–30.Google Scholar

Greblikas, F, Escolar, M, Klopstock, T, et al. The FOsmetpantotenate Replacement Therapy (FORT) Pivotal Trial: Utilization of a novel primary efficacy outcome in patients with pantothenate kinase-associated neurodegeneration (abstract 25). Mov Disord. 2018;33(Suppl 2):S11-2.Google Scholar

Amaral, LL, Gaddikeri, S, Chapman, PR, et al. Neurodegeneration with brain iron accumulation: Clinicoradiological approach to diagnosis. J Neuroimaging. 2015;25(4):539–51.Google Scholar

Delgado, RF, Sanchez, PR, Speckter, H, et al. Missense PANK2 mutation without “eye of the tiger” sign: MR findings in a large group of patients with pantothenate kinase-associated neurodegeneration (PKAN). J Magn Reson Imaging. 2012;35(4):788–94.Google Scholar

Schenck, JF, Zimmerman, EA. High-field magnetic resonance imaging of brain iron: Birth of a biomarker? NMR Biomed. 2004;17(7):433–45.Google Scholar

Stankiewicz, J, Panter, SS, Neema, M, et al. Iron in chronic brain disorders: Imaging and neurotherapeutic implications. Neurotherapeutics. 2007;4(3):371–86.Google Scholar

Fermin-Delgado, R, Roa-Sanchez, P, Speckter, H, et al. Involvement of globus pallidus and midbrain nuclei in pantothenate kinase-associated neurodegeneration: Measurement of T2 and T2* time. Clin Neuroradiol. 2013;23(1):11–5.Google Scholar

Chiapparini, L, Savoiardo, M, D’Arrigo, Set al. The “eye-of-the-tiger” sign may be absent in the early stages of classic pantothenate kinase associated neurodegeneration. Neuropediatrics. 2011;42(4):159–62.Google Scholar

Grandas, F, Fernandez-Carballal, C, Guzman-de-Villoria, J, Ampuero, I. Treatment of a dystonic storm with pallidal stimulation in a patient with PANK2 mutation. Mov Disord. 2011;26(5):921–2.Google Scholar

Awasthi, R, Gupta, RK, Trivedi, R, et al. Diffusion tensor MR imaging in children with pantothenate kinase-associated neurodegeneration with brain iron accumulation and their siblings. AJNR Am J Neuroradiol. 2010;31(3):442–7.Google Scholar

Haack, TB, Hogarth, P, Gregory, A, Prokisch, H, Hayflick, SJ. BPAN: The only X-linked dominant NBIA disorder. Int Rev Neurobiol. 2013;110:85–90.Google Scholar

Schneider, SA, Neurodegenerations with brain iron accumulation. Parkinsonism Relat Disord. 2016;22:S21–5.Google Scholar

Schneider, SA, Bhatia, KP, Hardy, J. Complicated recessive dystonia parkinsonism syndromes. Mov Disord. 2009;24(4):490–9.Google Scholar

Kell, DB. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol. 2010;84(11):825–89.Google Scholar

Di Meo, I, Tiranti, V. Classification and molecular pathogenesis of NBIA syndromes. Eur J Paediatr Neurol. 2018;22(2):272–84.Google Scholar

Tello, C, Darling, A, Lupo, V, Perez-Duenas, B, Espinos, C. On the complexity of clinical and molecular bases of neurodegeneration with brain iron accumulation. Clin Genet. 2018;93(4):731–40.Google Scholar

Svingen, L, Goheen, M, Godfrey, R, et al. Late diagnosis and atypical brain imaging of Aicardi–Goutières syndrome: Are we failing to diagnose Aicardi–Goutières syndrome-2? Dev Med Child Neurol. 2017;59(12):1307–11.Google Scholar

Sferra, A, Baillat, G, Rizza, T, et al. TBCE Mutations cause early-onset progressive encephalopathy with distal spinal muscular atrophy. Am J Hum Genet. 2016;99(4):974–83.Google Scholar

Gautschi, M, Merlini, L, Calza, AM, et al. Late diagnosis of fucosidosis in a child with progressive fixed dystonia, bilateral pallidal lesions and red spots on the skin. Eur J Paediatr Neurol. 2014;18(4):516–9.Google Scholar

Zoons, E, de Koning, TJ, Abeling, NG, Tijssen, MA. Neurodegeneration with brain iron accumulation on MRI: An adult case of alpha-mannosidosis. JIMD Rep. 2012;4:99–102.Google Scholar

Roubertie, A, Hieu, N, Roux, CJ, et al. AP4 deficiency: A novel form of neurodegeneration with brain iron accumulation? Neurol Genet. 2018;4(1):e217.Google Scholar

Dard, R, Meyniel, C, Touitou, V, et al. Mutations in DDHD1, encoding a phospholipase A1, is a novel cause of retinopathy and neurodegeneration with brain iron accumulation. Eur J Med Genet. 2017;60(12):639–42.Google Scholar

Vill, K, Muller-Felber, W, Alhaddad, B, et al. A homozygous splice variant in AP4S1 mimicking neurodegeneration with brain iron accumulation. Mov Disord. 2017;32(5):797–9.Google Scholar

Herebian, D, Alhaddad, B, Seibt, A, et al. Coexisting variants in OSTM1 and MANEAL cause a complex neurodegenerative disorder with NBIA-like brain abnormalities. Eur J Hum Genet. 2017;25(9):1092–5.Google Scholar

Meyer, E, Carss, KJ, Rankin, J, et al. Mutations in the histone methyltransferase gene KMT2B cause complex early-onset dystonia. Nat Genet. 2017;49(2):223–37.Google Scholar

Drecourt, A, Babdor, J, Dussiot, M, et al. Impaired transferrin receptor palmitoylation and recycling in neurodegeneration with brain iron accumulation. Am J Hum Genet. 2018;102(2):266–77.Google Scholar

Brunetti, D, Dusi, S, Giordano, C, et al. Pantethine treatment is effective in recovering the disease phenotype induced by ketogenic diet in a pantothenate kinase-associated neurodegeneration mouse model. Brain. 2014;137(Pt 1):57–68.Google Scholar

Orellana, DI, Santambrogio, P, Rubio, A, et al. Coenzyme A corrects pathological defects in human neurons of PANK2-associated neurodegeneration. EMBO Mol Med. 2016;8(10):1197–211.Google Scholar

Zhao, YG, Sun, L, Miao, G, et al. The autophagy gene Wdr45/Wipi4 regulates learning and memory function and axonal homeostasis. Autophagy. 2015;11(6):881–90.Google Scholar

Schultheis, PJ, Fleming, SM, Clippinger, AK, et al. Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited alpha-synuclein accumulation and age-dependent sensorimotor deficits. Hum Mol Genet. 2013;22(10):2067–82.Google Scholar

Zhao, Z, Zhang, X, Zhao, C, et al. Protection of pancreatic beta-cells by group VIA phospholipase A(2)-mediated repair of mitochondrial membrane peroxidation. Endocrinology. 2010;151(7):3038–48.Google Scholar

Hogarth, P, Kurian, MA, Gregory, A, et al. Consensus clinical management guideline for pantothenate kinase-associated neurodegeneration (PKAN). Mol Genet Metab. 2017;120(3):278–87.Google Scholar

Klopstock, T, Tricta, F, Neumayr, L, et al. A randomized trial of deferiprone for pantothenate kinase-associated neurodegeneration (abstr 471). Mov Disord. 2018;33(Suppl 2):S219.Google Scholar

Elbaum, D, Beconi, MG, Monteagudo, E, et al. Fosmetpantotenate (RE-024), a phosphopantothenate replacement therapy for pantothenate kinase-associated neurodegeneration: Mechanism of action and efficacy in nonclinical models. PLoS One. 2018;13(3):e0192028.Google Scholar

Cif, L, Kurian, MA, Gonzalez, V, et al. Atypical PLA2G6-associated neurodegeneration: social communication impairment, dystonia and response to deep brain stimulation. Mov Disord Clin Pract. 2014;1(2):128–31.Google Scholar

Kinghorn, KJ, Castillo-Quan, JI, Bartolome, F, et al. Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction. Brain. 2015;138(Pt 7):1801–16.Google Scholar

Gregory, A, Kurian, MA, Maher, ER, Hogarth, P, Hayflick, S. PLA2G6-associated neurodegeneration. GeneReviews®. 2008;Jun 19 (updated Mar 23, 2017).Google Scholar

Dusek, P, Schneider, SA, Aaseth, J. Iron chelation in the treatment of neurodegenerative diseases. J Trace Elem Med Biol. 2016;38:81–92.Google Scholar

Timmermann, L, Pauls, KA, Wieland, K, et al. Dystonia in neurodegeneration with brain iron accumulation: Outcome of bilateral pallidal stimulation. Brain. 2010;133(Pt 3):701–12.Google Scholar

Metzler, DE. Transition metals in catalysis and electron transport. In Metzler, DE, Metzler, CM, editors. Biochemistry: The Chemical Reactions of Living Cells, 2nd edn. San Diego, CA: Harcourt/Academic Press; 2003, vol. 1, ch. 16.Google Scholar

Clayton, PT. Inherited disorders of transition metal metabolism: An update. J Inherit Metab Dis. 2017;40(4):519–9.Google Scholar

King, D, Siau, K, Senthil, L, Kane, KF, Cooper, SC. Copper deficiency myelopathy after upper gastrointestinal surgery. Nutr Clin Pract. 2018;33(4):515–9.Google Scholar

van Hasselt, PM, Clayton, PT, Houwen, RHJ. Disorders of the transport of copper, iron, magnesium, manganese, selenium and zinc. In Saudubray, J-M, Baumgartner, MR, Walter, J, editors. Inborn Metabolic Diseases. Berlin: Springer; 2016, pp. 531–50.Google Scholar

Hlynialuk, CJ, Ling, B, Baker, ZN, et al. The mitochondrial metallochaperone SCO1 is required to sustain expression of the high-affinity copper transporter CTR1 and preserve copper homeostasis. Cell Rep. 2015;10(6):933–43.Google Scholar